An observational study in Treatment Resistant Depression, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Depressive Disorder, Treatment-Resistant with a site in France — 9 open to participants now, 10 under way, 1 of them phase 3. Depressive Disorder, Treatment-Resistant · France.
Among the 23 studies in Depressive Disorder, Treatment-Resistant with a site in France, this one is one of 4 that started in 2024, is one of 2 observational ones, and was the 15th registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →9 of the 23 studies in Depressive Disorder, Treatment-Resistant with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier St Anne · Sites in France
Ages 18+
Centre Hospitalier St Anne · Sites in France
Ages 18+
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Hôpital le Vinatier · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 73 across 50 observational studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 119 across the 21 interventional studies, 60 across the 2 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 23 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 2 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
2 of the studies in Depressive Disorder, Treatment-Resistant with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05577247Assistance Publique - Hôpitaux de ParisBelief Updating in Treatment Resistant Depression | 2026-12-13 |
| NCT05661383Hôpital le VinatierOlfactory and Brain Stimulations in Treatment-resistant Depression | 2027-01-27 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Depressive Disorder, Treatment-Resistant with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Major depressive disorder (MDD) is characterized by a cognitive triad of negative beliefs about oneself, the future and the world. For example, depressed patients hold persistently negative expectations about the future, despite contradictory evidence, and these strong negative beliefs are thought to play an important role in the maintenance of depressive symptoms and potentially in treatment resistance. Indeed, one out of three patients with major depressive disorder does not respond to conventional, monoaminergic treatments, which has led to the concept of treatment resistant depression (TRD). It is unknown how the brain encodes the strong negative beliefs that are insensitive to positive disconfirming information in TRD patients, and how these neural underpinnings of maladaptive belief updating are altered by antidepressant treatment.
The principal objective of this study is to gain insight into the brain mechanisms of belief updating about the future in TRD patients before and after starting ketamine treatment. The results of this study are expected to provide a better understanding of the neurocognitive mechanisms of belief-updating in depressed patients, and how these mechanisms contribute to clinical improvement following ketamine antidepressant treatment.
Major depressive disorder is characterized by persistently negative expectations about the future, despite contradictory evidence, and these strong negative beliefs are thought to play an important role in the maintenance of depressive symptoms and potentially in treatment resistance. Importantly, some findings indicate that the mechanisms of clinical improvement involves reductions in negative biases in emotion processing, which is in line with cognitive theories of depression.
However, it has never been studied if and how antidepressant treatment changes cognitive biases, which are important for mental health, such as the good news/bad news bias in belief updating. Moreover, it is also unknown how the brain of TRD patients encodes the strong negative beliefs that are insensitive to positive disconfirming information.
The study's main goal is to test how the brain encodes belief updating in treatment resistant depressed patients before compared to early after starting an antidepressant treatment. The main outcome measure is an interaction between testing time (before vs. after a single antidepressant dose) and information valence (positive vs. negative belief disconfirming information) on the brain's oxygenation level dependent signal (BOLD).
The secondary aims involve testing how belief updating changes on the behavioral level and links to global clinical improvement measured in the clinical care setting. To test these aim the study will compare the good news/bad new bias in belief updating before and after ketamine treatment. Tes the correlation of global clinical improvement to the emergence of the good news/bad news bias following antidepressant treatment.Compare the good news/bad new bias in belief updating between two groups of patients treated either by ketamine or by classical monoaminergic antidepressants that are all administered in the patient's natural clinical care setting.
This study is monocentric. The patients receive antidepressant treatment as part of their routine medical care and are not randomly assigned to this treatment by the investigator (contrary to a clinical trial). The study will be run within a natural, measurement-based care setting.
All patients will be tested two times, before and 24 hours after the first dose of an antidepressant medication.
A total of 120 patients diagnosed with treatment resistant depression (TRD) will be enrolled in the proposed study. TRD is defined by non-response to at least two different antidepressant treatments.
To test the main aim of this study 60 of the 120 TRD patients will be tested with functional magnetic resonance imaging (fMRI) before or 24h after a single subanaesthetic ketamine infusion. To be able to test the secondary aims and to run correlational analyses 60 of the 120 patients will be tested solely on the behavioral level before or 24h after a single monoaminergic antidepressant.
Patients will be randomly assigned to one of two testing time point groups that will involve testing before or 24h after a first, single antidepressant treatment dosis. Randomization will be stratified to assure that each testing time group involves an equal number of participants.
All patients will perform a cognitive belief updating tasks, which comprises 40 trials during which patients will be presented on a trial-by-trial basis with 40 different adverse lifetime events and information about their likelihood of occurrence in the general population (base rates, BR). The adverse lifetime events and their actual base rates are from previously published work that used to measure belief updating biases in healthy participants and in depressed patients. In total, 80 adverse lifetime events will be randomly allocated to two lists of 40 lifetime events and their actual base rates (one list per testing time point).
Following the belief updating task participants will rate a subset of the 40 events on their positive/negative valence, familiarity, vividness, personal relevance (if already experienced in the past), controllability and emotional arousal using visual analogous scales (VAS, see annexe for the events rated). This measure will be used to control all analyses for potential confounds arising from inter-individual differences on them.
Within the patient's usual care setting the following clinical measures will be obtained for this study, and are part of the usual psychiatric evaluation:
To assess treatment resistance in unipolar TRD patients, the Maudsley Staging Method will be administered during the usual patient care setting by an experienced psychiatrist at baseline prior to the first dose of antidepressant treatment. Global clinical improvement will be measured with MADRS by the same psychiatrist trained in the administration of the MADRS. Information about age, gender, level of education will be collected and used as control variables in all statistical analyses.
Patient with treatment resistant depression (TRD)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Demographic criteria:
Diagnostic criteria, severity and clinical course:
Treatments/strategies/procedures:
o At the start of new antidepressant treatment involving glutamate receptor modulators.
Exclusion criteria:
Criteria relating to associated pathologies carrying specific risks:
Criteria associated with /procedures/interventions added by the research:
o Contra-indications for an MRI exam (metallic implant, pacemaker, artificial heart valve, brain vascular malformation, aneurysm clips, exposed by metallic fragments, artificial implants, peripheral or neuronal stimulator, insulin pump, intravenous catheter, epilepsy, metallic device, claustrophobia, unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly))
Criteria relating to vulnerable populations:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: functional magnetic resonance imaging
Other: functional magnetic resonance imaging
Patients treated with ketamine antidepressants will be tested with fMRI before or 24h after a single ketamine infusion administered in the clinical setting.
Blood oxygenation level dependant (BOLD) signal
BOLD signal measured with fMRI before or 24h after a single ketamine infusion
Time frame: 7 days
Belief updating behavioral measure
Patients will perform a belief updating task before and 24 after a single antidepressant treatment dosis. Clinical improvement will be measured by the MADRS scale.
Time frame: 7 days
Montgomery Asberg depression rating scale score,
Clinical improvement will be measured by the MADRS scale. (score between 0 (no problem) to 60)
Time frame: 7 days
prognostic expectancy rating of antidepressant efficacy
Anticipated clinical improvement will be measured by subjective expectancy ratings that are given before starting the antidepressant treatment.
Time frame: 7 days
Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.
Of 33 observational studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 65. This study's planned 31 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →
Assistance Publique - Hôpitaux de Paris →